References

1. Ansalone G, Giannantoni P, Santini M. The stratification and prevention of the arrhythmia risk in nonischemic dilated cardiomyopathy. G Ital Cardiol. 1998; 28(11): 1288-302. PubMed | Google Scholar


2. Lacoviello M, Monitillo F. Non-invasive evaluation of arrhythmic risk in dilated cardiomyopathy: from imaging to electrocardiographic measures. Wolrd J Cardiol. 2014; 6(7): 562-76. PubMed | Google Scholar


3. Klein H, Auricchio A, Reek S, Geller C. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-Heft and MADIT-II. Am J Cardiol. 1999; 83(5B): 91D-97D. PubMed | Google Scholar


4. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12; 353(9169): 2001-7. PubMed | Google Scholar


5. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006; 8: 746-837. PubMed | Google Scholar


6. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary. A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J. 2006; 27: 2099-140. PubMed | Google Scholar


7. Bollmann A, Husser D, Cannom DS. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators. Am J Cardiovasc Drugs. 2005; 5(6): 371-8. PubMed | Google Scholar


8. Karaoguz R, Maydanozcu S, Altun T, Güldal M, Akyürek O, Erol C. Appropriate ICD therapy in patients with idiopathic dilated cardiomyopathy: long term follow-up. Int Heart J. 2006; 47(5): 763-73. PubMed | Google Scholar


9. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA), and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008; 29: 2388-42. PubMed | Google Scholar


10. 2010 Focused Update of ESC Guidelines on device therapy in heart failure. An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy - Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J. 2010; 31: 2677-87. PubMed | Google Scholar


11. Connoly SJ, Hallstrom AP, Cappato R et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials - AVID, CSAH and CIDS studies.Antiarrhytymicvs implantable defibrillator study - Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000; 21: 2071-8. PubMed | Google Scholar


12. Moss A, Hall J, Cannom D et al. Improved survival with an implantable defibrillator in patients with cororary disease at high risk for ventricular arrhythmia - The MADIT trial. N Engl J Med. 1996; 335: 1933-40. PubMed | Google Scholar


13. Buxton A, Lee K, DiCarlo L et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden cardiac death. The MUSTT trial. N Engl J Med. 2000; 342: 1937-45. PubMed | Google Scholar


14. Moss AJ, Zareba W, Hall J et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002; 346: 877-83. PubMed | Google Scholar


15. Honhloser S, Kuck H, Dorian P et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004; 351: 2481-8. PubMed | Google Scholar


16. Bansch D, Antz M, Boczor S et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy. Circulation. 2002; 105: 1453-8. PubMed | Google Scholar


17. Strickberger S, Hummel J, Bartlett T et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with non ischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol. 2003 May 21; 41(10): 1707-12. PubMed | Google Scholar


18. Kadish A, Dyer A, Daubert P et al. Prophylactic defibrillator implantation in patients with non ischemic dilated cardiomyopathy. N Engl J Med. 2004; 350: 2151-8. PubMed | Google Scholar


19. Bardy GH, Lee KL, Mark DB et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) investigators - Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352: 225-37. PubMed | Google Scholar